Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PETITE: Pimecrolimus vs TCS in infants with AD
NCT00120523Phase 3Completed
- Sponsor
- Meda
- Start
- Apr 2004
- Primary completion
- Oct 2010
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of Pimecrolimus vehicle + topical corticosteroid in atopic dermatitis (AD) (2 arms), sponsored by Meda. Primary endpoints: Safety Assessed by Adverse Events at 5 years, Growth Velocity (Height) at 5 years and 2 more. Started Apr 2004; status: completed.
02
Drugs
Pimecrolimus vehicle + topical corticosteroid
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT00120523.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00120523.